Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inhibikase Therapeutics in a report released on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company will earn ($0.10) per share for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Inhibikase Therapeutics' current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics' Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.56) EPS.
Separately, Jefferies Financial Group started coverage on shares of Inhibikase Therapeutics in a report on Friday, November 8th. They issued a "buy" rating and a $8.00 price target for the company.
Read Our Latest Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Up 18.4 %
Inhibikase Therapeutics stock traded up $0.48 during midday trading on Monday, hitting $3.08. 260,007 shares of the stock were exchanged, compared to its average volume of 191,071. The stock has a market capitalization of $213.56 million, a PE ratio of -1.15 and a beta of 1.06. The company has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $2.20. Inhibikase Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.20.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Stifel Financial Corp acquired a new position in Inhibikase Therapeutics in the 4th quarter worth $43,000. Jefferies Financial Group Inc. bought a new position in Inhibikase Therapeutics in the fourth quarter valued at $48,000. Alpine Global Management LLC bought a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $48,000. Caxton Corp bought a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $53,000. Finally, Squarepoint Ops LLC acquired a new position in Inhibikase Therapeutics during the fourth quarter worth approximately $92,000. Institutional investors and hedge funds own 3.81% of the company's stock.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Read More
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
